The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
From medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact Areas
Explore stories, news, insights, and data across articles, videos, and podcasts.
view all content types
of all universities in the world*
locations
of the student body are Arab Israeli
The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Explore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATSATS is a community of supporters, innovators, and champions of possibility united by one mission: transforming Israel and the world through science and discovery.
Learn MoreFor more than 100 years, the Technion has been Israel's technological engine and leading driver of innovation, technology, and entrepreneurship, transforming ideas into impact.
Learn More
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreFrom medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact AreasExplore stories, news, insights, and data across articles, videos, and podcasts.
view all content typesExplore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATS
A breast cancer diagnosis can bring a terrifying question: Will chemotherapy save my life, or will I endure its painful side effects without any benefit? In this video, influencer Aija Mayrock sits down with Dr. Gil Shamai, a postdoctoral researcher at the Technion – Israel Institute of Technology, to explore an AI breakthrough that could help doctors answer that question. After dedicating approximately 30,000 hours to this research, Gil and his team developed an AI model that analyzes tumor tissue images to predict whether breast cancer will return and whether chemotherapy is likely to help.
Validated using data from more than 10,000 patients in a major clinical trial, the technology could help spare patients unnecessary treatment, reduce the financial burden of cancer care and make personalized treatment more accessible worldwide. Watch Aija’s conversation with Dr. Shamai to discover how Technion researchers are harnessing AI to transform breast cancer treatment and potentially change millions of lives.
October 15, 2026
Discover how AI for breast cancer treatment could help doctors predict chemotherapy benefit and spare some patients unnecessary treatment.
1 min
X (opens in a new tab) / Facebook (opens in a new tab) / LinkedIn (opens in a new tab) / Email / Copy Link
Breast Cancer / AI / Faculty /
A Breakthrough From the Technion Together with collaborators from leading medical centers in Israel, the United States, Europe, and Australia, Shamai and his team at the Technion have developed an AI model that predicts both the risk that breast cancer will return and whether a patient is likely to benefit from chemotherapy — offering a […]
An Israeli medical researcher has helped shed new light on a mystery that has endured for nearly 340 years: what killed Queen Christina of Sweden, one of 17th-century Europe’s most unusual monarchs. Prof. Zaid Abassi of the Technion – Israel Institute of Technology’s, Ruth and Bruce Rappaport Faculty of Medicine and Rambam Health Care Campus, […]
Artificial intelligence is rapidly becoming an integral part of our lives, and a working tool for professionals in a variety of fields, including medicine, which integrates AI in order to reach faster, more accurate, and more efficient diagnoses. But to what extent can AI truly be relied upon when it comes to complex medical decisions? […]
Stay on top of the latest breaking scientific discoveries from Israel and the Technion. Subscribe to the ATS newsletter.